Skip to content

Insulin Regular Human

    Brands

    DEA Class; Rx, OTC

    Common Brand Names; Humulin R, Novolin R, Humulin R U-500, Myxredlin

    • Antidiabetics, Insulins; 
    • Antidiabetics, Short-Acting Insulins

    Regular insulin U-100 is short-acting insulin; concentrated regular insulin U-500 exhibits characteristics of immediate-acting insulins
    Used for type 1 and 2 diabetes mellitus in adult and pediatric patients; also used for hyperglycemic crises and blood glucose management in critical and other care settings
    Ensure the correct regular insulin concentration is used to avoid severe overdose and hypoglycemia

    Indicated for the treatment type 2 diabetes mellitus.

    For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (type 1 or type 2) who are now pregnant.
    For the treatment of diabetic ketoacidosis (DKA).
    For the treatment of hyperosmolar hyperglycemic state (HHS) in patients with type 2 diabetes mellitus.
     
    For the treatment of type 1 diabetes mellitus.
    For the treatment of neonatal diabetes mellitus.
    For nutritional supplementation to maintain normoglycemia in very low birthweight infants with persistent glucose intolerance, including those neonates on parenteral nutrition with persistent glucose intolerance.
    For the treatment of hyperkalemia.
    For the treatment of beta-blocker toxicity or calcium-channel blocker toxicity.

    Hypersensitivity to product or excipients

    Hypoglycemia

    Intensification or rapid improvement in glucose control associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy

    Hypersensitivity reactions

    Severe, life-threatening, generalized allergy, including anaphylaxis

    Hypoglycemia

    Hypokalemia

    Peripheral edema

    Weight gain

    Immunogenicity

    Injection site reactions

    Localized cutaneous amyloidosis

    Never share pen, needles, or syringes between patients

    Use with caution in patients with decreased insulin requirements: Diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, and hepatic impairment

    Use with caution in patients with increased insulin requirements: Fever, hyperthyroidism, trauma, infection, and surgery

    Severe, life-threatening, generalized allergy, including anaphylaxis, can occur; discontinue therapy if indicated

    Not for mixing with any insulin for intravenous use or with insulins other than NPH insulin for subcutaneous use

    Insulins may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy

    Weight gain can occur with insulins and has been attributed to anabolic effects of insulin

    Use caution in pregnancy

    Available data from published studies over decades have not established association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes

    Available data from published literature suggests that exogenous human insulin products, are transferred into human milk

    Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

    Insulin regular human

    Regular, human insulin rDNA origin

    injectable solution

    • OTC
      • 100units/mL (3mL vial)
      • 100units/mL (10mL vial)
    • Rx
      • 500units/mL (20mL vial); prescribe with U-500 syringes to avoid conversion for U-100 tuberculin syringes
      • 500units/mL (3mL pen)
      • 100units/100mL 0.9% NaCl (Myxredlin)